Description: BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Home Page: www.beigene.com
94 Solaris Avenue
Camana Bay,
KY1-1108
Cayman Islands
Phone:
345-949-4123
Officers
| Name | Title |
|---|---|
| Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO |
| Dr. Xiaobin Wu Ph.D. | President & COO |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder |
| Mr. Chan Lee | General Counsel & Senior VP |
| Mr. Wang Lai Ph.D. | Global Head of R&D |
| Mr. Aaron Rosenberg | CFO & Principal Financial Officer |
| Mr. Titus B. Ball | VP & Chief Accounting Officer |
| Ms. Liza Heapes | Head of Investor Relations |
| Mr. Yang Ji | Chief Compliance Officer |
| Dr. Yan Qi | Senior VP & Head of Public Affairs - Greater China |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 384.6154 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.3873 |
| Price-to-Sales TTM: | 0.9093 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10600 |